- Home
- GALT vs QSI Comparison
GALT vs QSI Comparison
Compare GALT & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | QSI |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | 145 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 194.8M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | GALT | QSI |
|---|---|---|
| Price | $2.53 | $1.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $8.50 | $1.00 |
| AVG Volume (30 Days) | 348.5K | ★ 6.3M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $618.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.27 | $0.69 |
| 52 Week High | $7.13 | $3.10 |
Technical Indicators
Market Signals| Indicator | GALT | QSI |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 66.17 |
| Support Level | $2.09 | $1.15 |
| Resistance Level | $2.60 | $1.33 |
| Average True Range (ATR) | 0.23 | 0.08 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 44.71 | 88.43 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.